Australian pharmaceutical company Bioxyne Limited has received its first commercial order for psilocybin capsules, marking a significant step in the country’s emerging market for psychedelic therapies. The order, secured through Bioxyne’s subsidiary Breathe Life Sciences (BLS), comprises 250 doses of GMP-manufactured psilocybin capsules (BLSPSIL25) destined for authorized prescribers in Queensland and Western Australia.
The capsules are intended for the treatment of patients with treatment-resistant depression (TRD), with approximately 60 patients expected to receive the therapy over the next twelve months. This development comes after Australia became the first nation globally to permit the prescription of psilocybin for TRD by authorized psychiatrists in July 2023.
Bioxyne’s ability to produce psilocybin capsules to Good Manufacturing Practice (GMP) standards positions the company as a key player in the nascent Australian market. GMP certification ensures quality, purity, and dosage accuracy – critical factors for a substance intended for therapeutic use. The company holds a TGA-GMP license, adhering to both Australian and international pharmaceutical standards.
The move by Bioxyne occurs alongside growing international interest in psilocybin as a potential treatment for mental health conditions. Compass Pathways, a US-based company, has been conducting Phase 3 trials of its own psilocybin formulation for depression, garnering significant attention and investment. Recent Phase 3 trial results from Compass Pathways have raised hopes for potential FDA approval, according to a report by Forbes.
However, Bioxyne is pursuing a different strategy than Compass Pathways, focusing on GMP-compliant manufacturing and early commercial supply chains rather than late-stage clinical development. This approach allows the company to capitalize on existing regulatory pathways and directly serve the Australian market.
The potential market for psilocybin-assisted therapy in Australia is substantial. The Australian Bureau of Statistics estimates that approximately 4.9% of Australians between the ages of 16 and 85 experienced a depressive episode within a year – roughly one million people. Around 30% of those with major depressive disorder are considered to have TRD, representing an addressable market of approximately 300,000 patients.
Bioxyne plans to scale production to meet potential demand, with plans to introduce capsules with varying dosages, including BLSPSIL10 and BLSPSIL15. The company also has experience in the medical cannabis sector in Australia, the UK, and Europe, and has begun supplying GMP-MDMA capsules for clinical trials and authorized prescribers.
The initial order also includes provisions for exploratory research into other mental health conditions, including anxiety disorders, substance use disorder, and PTSD. Bioxyne CEO Sam Watson stated that the company is “translating its psychedelic manufacturing capabilities into early commercial results and positive patient outcomes.”
Analysts predict significant growth in the global market for psychedelic medicines, potentially reaching $8-13 billion by the early 2030s. Regulatory changes and increasing clinical evidence are driving this expansion. Germany launched a compassionate-use program for TRD in 2025, and the Czech Republic is planning a regulated medical use of psilocybin for severe, treatment-resistant depression starting in 2026, even as Switzerland already has an established framework.
